UK markets closed
  • FTSE 100

    6,483.43
    -168.53 (-2.53%)
     
  • FTSE 250

    20,910.37
    -287.75 (-1.36%)
     
  • AIM

    1,183.25
    -8.61 (-0.72%)
     
  • GBP/EUR

    1.1537
    +0.0039 (+0.34%)
     
  • GBP/USD

    1.3921
    -0.0091 (-0.65%)
     
  • BTC-GBP

    34,150.91
    +176.41 (+0.52%)
     
  • CMC Crypto 200

    912.88
    -20.25 (-2.17%)
     
  • S&P 500

    3,811.15
    -18.19 (-0.48%)
     
  • DOW

    30,932.37
    -469.64 (-1.50%)
     
  • CRUDE OIL

    61.66
    -1.87 (-2.94%)
     
  • GOLD FUTURES

    1,733.00
    -42.40 (-2.39%)
     
  • NIKKEI 225

    28,966.01
    -1,202.26 (-3.99%)
     
  • HANG SENG

    28,980.21
    -1,093.96 (-3.64%)
     
  • DAX

    13,786.29
    -93.04 (-0.67%)
     
  • CAC 40

    5,703.22
    -80.67 (-1.39%)
     

Global $35.63 Billion Hepatitis B Virus (HBV) Market to 2030: Focus on European Union, United States & Japan

Research and Markets
·5-min read

Dublin, Feb. 23, 2021 (GLOBE NEWSWIRE) -- The "Global Hepatitis B Virus (HBV) Market: 10 Year Demand Forecast & Impact of COVID-19 (2021-2030)" report has been added to ResearchAndMarkets.com's offering.

The global hepatitis B virus (HBV) market is expected to reach US$35.63 billion in 2030, increasing at a CAGR of 29.41%, for the period of 2021-2030.

The factors such as growth of pharmaceutical industry, increase in ageing population, upsurge in healthcare expenditure, urbanization leading to better monitoring and screening procedures and increase in liver cancer and cirrhosis deaths due to HBV would drive the growth of the market.

However, the market growth would be challenged by rigid competition, management challenges, lack of diagnostic facilities and high cost of medical care and legal regulations. A few notable trends may include growth in pharmaceutical research and development, collaboration, innovation and research, high demand for biomarker based tests, HBV treatments in development and government initiatives and public awareness.

The HBV market is fragmented in nature and the degree of fragmentation would accelerate during the forecast period. To make the most of the opportunities, market players are focusing more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

Key players are investing significant amount of funds on the pharmaceutical research and development in order to expand the product portfolio of hepatitis B therapeutics, which is likely to help in the considerable growth of the global hepatitis b virus (HBV) market.

The fastest regional market is the U.S., due the presence of the well established healthcare infrastructure. With the increase in the prevalence of hepatitis B, the demand for treatment of the disease is becoming prominent.

Therefore, some of the government and non-government organizations are taking the initiative to bring awareness about hepatitis B, which would help in the growth of the global HBV market in coming years.

Scope of the report:

  • The report provides a comprehensive analysis of the global Hepatitis B Virus (HBV) Market.

  • The major regional markets (the U.S., European Union and Japan) have been analyzed.

  • The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.

  • The competitive landscape of the market, along with the company profiles of leading players (Johnson & Johnson, Merck & Co., Bristol-Myers Squibb, Gilead Sciences, Arrowhead Pharmaceuticals and Arbutus Pharma are also presented in detail.

Key Target Audience:

  • Hepatitis B Virus Therapeutics Manufacturers

  • Pharmaceuticals and Biopharmaceutical Firms

  • End Users (Hospitals and Research Institutes)

  • Investment Banks

  • Healthcare and Medical Consultants

  • Government Bodies & Regulating Authorities

Key Topics Covered:

1. Market Overview
1.1 HBV: Introduction
1.2 Causes of Hepatitis B
1.3 Symptoms of Hepatitis B
1.4 Test and Diagnosis of Hepatitis B
1.5 Risk of Hepatitis B
1.6 HBV Blood Tests
1.7 Chronic HBV Disease Phases
1.8 Current HBV Treatments

2. Impact of COVID-19
2.1 Growth in Government Spending on Healthcare
2.2 COVID-19 Antiviral Drugs Candidates
2.3 Chloroquine and COVID-19

3. Global HBV Market Analysis
3.1 Global HBV Market
3.2 Global HBV Market by Antiviral Drug Class
3.2.1 Global RNA Interference Antiviral Market Forecast by Value
3.2.2 Global Entry Inhibitor Antiviral Market Forecast by Value
3.2.3 Global Core Inhibitor Antiviral Market Forecast by Value
3.2.4 Global Antisense Antiviral Market Forecast by Value
3.2.5 Global HBsAg Inhibitors Antiviral Market Forecast by Value

4. Regional Market Analysis
4.1 The US
4.1.1 The US HBV Market Forecast by Value
4.1.2 The US Chronic HBV Patients Forecast by Volume
4.1.3 The US Diagnosed HBV Patients Forecast by Volume
4.1.4 The US Treated HBV Patients Forecast by Volume
4.2 European Union
4.2.1 European Union HBV Market Forecast by Value
4.2.2 European Union Chronic HBV Patients Forecast by Volume
4.2.3 European Union Diagnosed HBV Patients Forecast by Volume
4.2.4 European Union Treated HBV Patients Forecast by Volume
4.3 Japan
4.3.1 Japan HBV Market Forecast by Value

5. Market Dynamics
5.1 Growth Drivers
5.1.1 Expansion of Pharmaceutical Industry
5.1.2 Increase in Ageing Population
5.1.3 Increasing Healthcare Expenditure
5.1.4 Urbanization leading to Better Monitoring and Screening Procedures
5.1.5 Increase in Liver Cancer and Cirrhosis Deaths due to HBV
5.2 Market Trends
5.2.1 Growth in Pharmaceutical Research and Development
5.2.2 Collaboration, Innovation and Research
5.2.3 High Demand for Biomarker Based Tests
5.2.4 HBV Treatments in Development
5.2.5 Government Initiatives and Public Awareness
5.3 Challenges
5.3.1 Rigid Competition
5.3.2 Management Challenges
5.3.3 Lack of Diagnostic Facilities and High cost of Medical Care
5.3.4 Legal Regulations

6. Competitive Landscape
6.1 Key Players - Revenue Comparison
6.2 Key Players - R&D Expenditure Comparison
6.3 Key Players - Market Capitalization Comparison
6.4 Global HBV Therapies in Development by Company
6.5 Global Capsid Inhibitor Therapy in Development by Company
6.6 Global RNAi Gene Silencer Therapy in Development by Company

7. Company Profiles
7.1 Johnson & Johnson
7.1.1 Business Overview
7.1.2 Financial Overview
7.1.3 Business Strategies
7.2 Merck and Co.
7.3 Bristol-Myers Squibb
7.4 Gilead Sciences
7.5 Arrowhead Pharmaceuticals
7.6 Arbutus Pharma

For more information about this report visit https://www.researchandmarkets.com/r/e3xkm8


CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900